Target intelligence / Profile preview

Tumor necrosis factor receptor superfamily member 4 (OX40) (OX40)

Target
OX40
Molecular classification
Receptor, Tumor necrosis factor receptor superfamily
01

Overview

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4), also known as OX40 or CD134, is a type I transmembrane glycoprotein and a potent costimulatory receptor primarily expressed on activated T cells. It belongs to the tumor necrosis factor receptor (TNFR) superfamily and interacts with its ligand, OX40L (TNFSF4), which is typically expressed on antigen-presenting cells like dendritic cells and B cells. The OX40-OX40L interaction is crucial for the survival and expansion of effector T cells and the development of memory T cells, while also inhibiting the suppressive function of regulatory T cells (Tregs). In oncology, agonistic antibodies targeting OX40 are designed to enhance anti-tumor immunity by boosting T-cell activity and overcoming the immunosuppressive tumor microenvironment. In contrast, for autoimmune and inflammatory diseases such as atopic dermatitis, antagonistic antibodies or OX40-depleting agents are used to reduce the activity of pathogenic T cells. While OX40-targeted therapies show promise, clinical development faces challenges including the risk of cytokine release syndrome and the need for precise patient selection based on receptor expression levels. Current research is also exploring the synergy of OX40 agonists with other checkpoint inhibitors like PD-1 blockers to improve therapeutic outcomes in solid tumors.

Other names
CD134ACT35TXGP1LOX40 antigenTax-transactivation-responsive albumin-binding protein
02

Mechanism of action

Agonism of costimulatory signaling to enhance T-cell effector function (oncology); Antagonism or depletion of activated T cells to suppress immune response (autoimmune/inflammatory).

03

Biological functions

Immune responseT-cell activationT-cell proliferationT-cell survivalCytokine productionMemory T-cell formation
04

Disease associations

CancerAtopic dermatitisAsthmaSystemic lupus erythematosusRheumatoid arthritisGraft-versus-host disease
05

Safety considerations

Cytokine release syndromeImmune-related adverse eventsInfusion-related reactionsPotential for systemic autoimmunity
06

Interacting drugs

7 more in the full profile.

07

Biomarkers

OX40 expression on tumor-infiltrating lymphocytesOX40L expression on antigen-presenting cellsSoluble OX40 levels

Beyond the preview

Go deeper on Tumor necrosis factor receptor superfamily member 4 (OX40) (OX40).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tumor necrosis factor receptor superfamily member 4 (OX40) (OX40).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call